Nanoparticle 'Booster' tested to make radiation hit harder against tough lung cancer
NCT ID NCT04505267
Summary
This early-stage study is testing a new nanoparticle drug called NBTXR3 for people with inoperable, recurrent non-small cell lung cancer. The nanoparticle is injected directly into the tumor and is designed to make standard radiation therapy more powerful at killing cancer cells, while aiming to spare healthy tissue. The main goals are to find the safest and most effective dose and to see what side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.